Autonomous Therapeutics is a private, preclinical-stage biotech founded in 2016 and headquartered in Cambridge, MA, with a major R&D facility in Rockville, MD. The company is developing a novel class of 'Encrypted RNA' therapeutics designed to be activated only in target cells and to overcome resistance mechanisms, addressing a broad range of diseases. It has secured significant non-dilutive and venture funding from prestigious government agencies and investors, including DARPA, NIH, BARDA, and Third Kind Venture Capital, validating its innovative platform technology.
Infectious DiseaseOncology
Technology Platform
Encrypted RNA™ (target-activated nucleic acids) and Therapeutic Interfering Particles (TIPs) for escape-resistant antiviral therapy.
Funding History
2
Total raised:$6.6M
Grant$2.1MDARPA
Seed$4.5MIndieBio
Opportunities
The company's platforms address massive unmet needs in both infectious disease and oncology with potentially paradigm-shifting approaches: single-dose, resistance-proof antivirals and highly precise, tumor-activated RNA therapies.
Strong validation and funding from top-tier government agencies de-risk the technology and provide a pathway for advanced development and potential strategic partnerships.
Risk Factors
The core technologies, while promising, are novel and unproven in human trials, carrying high technical and clinical development risk.
The company is also operating in highly competitive therapeutic areas against large, well-resourced competitors, requiring clear differentiation to succeed.
Competitive Landscape
In RNA therapeutics, Autonomous competes with giants like Moderna and BioNTech, as well as numerous biotechs, but differentiates through its target-activated 'Encrypted RNA' mechanism. In antivirals, its TIPs platform offers a unique evolutionary trap mechanism distinct from traditional small molecules or monoclonal antibodies, potentially competing with next-generation antivirals from large pharma.
